ClinicalTrials.gg
CompletedNCT00320775Updated Mar 18, 2015

Safety and Tolerability Study of Intravitreal VEGF-Trap Administration in Patients With Neovascular AMD

A Phase 1 interventional study of VEGF Trap in Macular Degeneration, sponsored by Regeneron Pharmaceuticals. Completed at 8 sites in United States. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2015-03-18.

Sponsored by Regeneron Pharmaceuticals · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
51
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 67 studies testing aflibercept in Macular Degeneration — 3 open to participants now, 6 under way, 2 of them phase 3. aflibercept · Macular Degeneration.

Enrollment
35th of 67
51 · median 54
Started
2005
the only one that year
Phase 1
6 of 67
1 open now
Registered
1st of 67
by date
Lead sponsor
10 of 67
Regeneron Pharmaceuticals

Among the 67 studies testing aflibercept in Macular Degeneration, this one is the 35th largest by enrollment, is the only one that started in 2005, is one of 6 in phase 1, and was the 1st registered.

Macular Degeneration

1,461 studies on the registry are indexed under Macular Degeneration; 237 are open to participants now.

Browse Macular Degeneration studies →

Open to participants now

3 of the 67 studies testing aflibercept in Macular Degeneration are open now, in 9 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About aflibercept

aflibercept: first FDA approval 2011 (EYLEA), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 166 Macular Degeneration studies recruiting now, 117 (70%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 67 studies testing aflibercept in Macular Degeneration, or all of them as a file.
02

Study summary

The purpose of this trial is to assess the ocular and systemic safety and tolerability of a single intravitreal injection of VEGF Trap in patients with subfoveal choroidal neovascularization (CNV) due to AMD.

Read the detailed description

This study consists of three parts, Part A, Part B and Part C. Part A is a dose escalation. Part B was terminated early. The (one) subject who received Macugen is not discussed in this website. Part C had subjects receive one of two doses of VEGF Trap (0.15 mg or 4.0 mg).

This is the first study in which human subjects received intravitreal injections of VEGF Trap in a study eye.

03

Conditions studied

  • Macular Degeneration

Keywords

  • Neovascular Age-Related Macular Degeneration
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subfoveal CNV secondary to AMD.
  • Central retinal/lesion thickness ≥ 250µm as measured by optical coherence tomography (OCT).
  • ETDRS best-corrected visual acuity of:

    • 20/40 (73 letters) or worse
  • Clear ocular media and clear lens(es) to permit good quality stereoscopic fundus photography.

Exclusion criteria

Exclusion Criteria:

  • Prior treatment with VEGF Trap, bevacizumab or ranibizumab.
  • Any agent within 12 weeks of Visit 2 (Day 1).
  • Presence of other causes of CNV.
  • Active ocular infection.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
51 participants (actual)

Study arms

  • Experimental
    Part A

    Part A: An open label study in which six successive cohorts of 3-6 patients each with neovascular AMD will receive a single intravitreal (ITV) injection of 0.05, 0.15, 0.5, 1.0, 2.0, or 4.0 mg of VEGF Trap into the study eye. The total volume of each injection will be 100 μL. Enrollment in new dose levels will not begin until all patients in the preceding dose level have completed Visit 5 (Day 15).

    Drug: VEGF Trap

  • Active comparator
    Part B

    Part B: A controlled, prospective, randomized, double-masked study in which up to 30 subjects meeting eligibility criteria will be randomly assigned in a 1:1 ratio to receive a single ITV injection of2.0 mg/eye VEGF Trap (or the MTD if reached prior to 2.0 mg) followed by 1 sham injection six weeks later, or an initial dose of 0.3 mg pegaptanib sodium into the study eye, followed by a second dose six weeks later. Enrollment into Part B will begin 2 weeks after the last subject to receive the 2.0 mg/eye dose in Part A has been observed for 15 days and it has been determined that the safety profile of VEGF Trap at this dose level is adequate to support expansion of dosing at this dose level. The dose of pegaptanib sodium will be 0.3 mg, according to the package insert.

    Drug: VEGF Trap

  • Active comparator
    Part C

    Part C: A controlled, prospective, randomized, double-masked study in which approximately 30 subjects meeting eligibility criteria will be randomly assigned in a 1:1 ratio to receive up to two ITV injections of either 0.15 or 4.0 mg/eye VEGF Trap. Initiation of Part C is contingent upon the 4.0 mg dose being adequately tolerated in Part A.

    Drug: VEGF Trap

Interventions

  • Part A: Six successive cohorts of 3-6 patients each with neovascular AMD will receive a single intravitreal (ITV) injection of 0.05, 0.15, 0.5, 1.0, 2.0, or 4.0 mg of VEGF Trap into the study eye. Part B: Up to 30 subjects will be randomly assigned in a 1:1 ratio to receive a single of 2.0 mg/eye VEGF Trap followed by 1 sham injection six weeks later, or an initial dose of 0.3 mg pegaptanib sodium into the study eye, followed by a second dose six weeks later. Part C: Approximately 30 subjects will be randomly assigned in a 1:1 ratio to receive up to two ITV injections of either 0.15 or 4.0 mg/eye VEGF Trap. After completion of Visit 8 (Day 57), patients from all parts of the study, may be eligible to continue in Open-label Extension and will receive 4.0 mg of VEGF Trap.

    Also known as: Aflibercept

06

What researchers measure

Primary outcomes

  1. Safety and tolerability, bioeffect

    Time frame: From baseline to Day 43

Secondary outcomes

  1. The effect of VEGF Trap administration on excess central retinal/lesion thickness

    Time frame: From baseline to Day 43

  2. Best-corrected Early Treatment of Diabetic Retinopathy Study (ETDRS) visual acuity

    Time frame: From baseline to Day 43

  3. Extent of CNV leakage

    Time frame: From baseline to Day 43

  4. Anti-VEGF Trap antibodies in the systemic circulation

    Time frame: From baseline to Day 43

  5. Plasma levels of VEGF Trap

    Time frame: From baseliene to Day 43

07

Study locations

8 sites
  • Retina Centers, PC
    Tuscon, Arizona 85704, United States
  • Loma Linda University Health Care
    Loma Linda, California 92354, United States
  • University of Chicago
    Chicago, Illinois 60637, United States
  • Johns Hopkins Hospital School of Medicine
    Baltimore, Maryland 21287, United States
  • Charlotte Eye, Ear, Nose & Throat Asssociates
    Charlotte, North Carolina 28120, United States
  • Dean A. McGee Eye Institute
    Oklahoma City, Oklahoma 73104, United States
  • Retina Diagnostic and Treatment Assoc., LLC
    Philadelphia, Pennsylvania 19107, United States
  • Retina-Vitreous Associates, P.C.
    Nashville, Tennessee 37203, United States
08

References and documents

Publications

  • Nguyen QD, Campochiaro PA, Shah SM, Browning DJ, Hudson HL, Sonkin PL, Hariprasad SM, Kaiser PK, Slakter J, Haller JA, Do DV, Mieler W, Chu K, Ingerman A, Vitti R, Berliner AJ, Cedarbaum J; Clear-It 1 Investigators. Evaluation of very high- and very low-dose intravitreal aflibercept in patients with neovascular age-related macular degeneration. J Ocul Pharmacol Ther. 2012 Dec;28(6):581-8. doi: 10.1089/jop.2011.0261. Epub 2012 Jul 9. PubMed 22775078 ↗
  • Do DV, Schmidt-Erfurth U, Gonzalez VH, Gordon CM, Tolentino M, Berliner AJ, Vitti R, Ruckert R, Sandbrink R, Stein D, Yang K, Beckmann K, Heier JS. The DA VINCI Study: phase 2 primary results of VEGF Trap-Eye in patients with diabetic macular edema. Ophthalmology. 2011 Sep;118(9):1819-26. doi: 10.1016/j.ophtha.2011.02.018. Epub 2011 May 5. PubMed 21546089 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2005, a primary completion of Jun 2008 and a completion of Aug 2008. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 28, 2006
First posted
May 3, 2006
Start
Jun 2005
Primary completionActual
Jun 2008
CompletionActual
Aug 2008
Last update
Mar 18, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 18, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00320775
Collaborators
Bayer
Responsible party
Sponsor
First posted
May 3, 2006
Start date
Jun 2005
Primary completion
Jun 2008
Completion
Aug 2008
Last update
Mar 18, 2015

Study contacts

Avner Ingerman, MD
study director · Regeneron Pharmaceuticals

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aflibercept

Start the discussion